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Objectives. We sought to study the effects of short-acting and
long-acting nifedipine on the sympathetic nervous system (SNS),
heart rate (HR) and blood pressure (BP) of normotensive subjects
under baseline conditions and during SNS stimulation.
Background. Calcium channel antagonists in different pharma-
cokinetic formulations are widely used in patients with coronary
artery disease or hypertension. Short-acting formulations activate
the SNS, an action that may be disadvantageous in patients with
coronary disease, especially if left ventricular function is im-
paired. The effects of slow-release formulations on the SNS are
unknown.
Methods. We used microneurography to investigate the influ-
ence of nifedipine (5 mg; 10 mg; and slow-release [GITS], 60 mg)
on muscle sympathetic nerve activity (MSA) and skin sympathetic
nerve activity (SSA) in healthy volunteers.
Results. Peak plasma levels after short-acting and slow-release
nifedipine were achieved within 60 min and 330 min, respectively.
Short-acting (10 mg, n 5 10) and slow-release (n 5 10) nifedipine,
but not placebo, markedly activated MSA and increased plasma
norepinephrine; plasma endothelin increased only with slow-
release nifedipine. HR increased after short-acting nifedipine, but
not after nifedipine GITS. Nifedipine had no effect on SSA (n 5
6). Blockade of cardiac sympathetic activity (with esmolol) led to
similar decreases in HR with or without nifedipine, whereas
parasympatholysis (with atropine) led to similar increases in HR
with or without nifedipine. The cold pressor test markedly in-
creased MSA in all treatment groups and further increased MSA
beyond the increase induced by nifedipine.
Conclusions. Nifedipine markedly increased MSA, but not SSA,
independently of drug release formulation. In contrast, HR in-
creased with short-acting, but not with slow-release, nifedipine.
Therefore, nifedipine activates cardiac and peripheral sympa-
thetic nerves differently depending on pharmacokinetics. These
effects of nifedipine may be disadvantageous in cardiac patients
with increased sympathetic activity or congestive heart failure, or
both.
(J Am Coll Cardiol 1997;29:1607–14)
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Local or generalized vasoconstriction is an important mecha-
nism in several forms of cardiovascular disease. Augmented
vascular tone in the entire circulation accounts for arterial
hypertension (1). Focal vasoconstriction is an important mech-
anism in coronary spasm (2), contributes to coronary artery
disease in general (3) and is a typical feature of Raynaud’s
disease and migraine (4). Furthermore, in heart failure, in-
creased peripheral vascular resistance is a secondary phenom-
enon, but contributes importantly to symptoms and outcome
(5).
Calcium channel antagonists are effective antihypertensive
drugs and exert anti-ischemic effects (6). They also exhibit
vascular protective properties; improve endothelial function in
atherosclerosis and hypertension, at least experimentally (7);
inhibit proliferation of human coronary artery smooth muscle
cells (8); and reduce atherosclerosis in hypercholesteremic
rabbits (9). In the human coronary circulation, dihydropyridine
calcium channel antagonists reduce the development of new
atherosclerotic lesions (10).
Despite these impressive vascular protective effects, clinical
trials with calcium channel antagonists have yielded some
disappointing results, particularly in patients with coronary
artery disease and impaired left ventricular function (11–16). A
potential mediator of untoward effects of cardiovascular drugs
is an activation of the sympathetic nervous system (SNS).
Overactivation of the SNS may be detrimental in acute coro-
nary syndromes (17) and heart failure (5,18,19). Activation of
the SNS may depend not only on the drug used, but also on its
pharmacokinetics; that is, the SNS may be stimulated particu-
larly with rapid, but not with delayed, onset of action. Hence,
we studied the effects of short-acting and long-acting nifedi-
pine on the SNS, heart rate (HR) and blood pressure (BP) in
normotensive subjects under baseline conditions and during
SNS stimulation.
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Methods
Study patients. Studies were performed in healthy volun-
teers. The subjects were free of cardiovascular or other dis-
eases as assessed by a medical history and a physical examina-
tion performed before the study. Written informed consent
was obtained from all subjects. The study was approved by the
ethical committee of the University Hospital (Inselspital),
Bern, Switzerland.
Experimental protocol. All subjects were studied in the
morning (9 AM) after a light breakfast. After micturition, to
avoid any stimulation of sympathetic nerve activity through
bladder distension, subjects were asked to resume the supine
position. The left or right leg was fixed by a vacuum cushion,
and electrocardiographic (ECG) leads, a blood pressure cuff
and respiration strain gauge were placed. A catheter (Venflon,
Ohmeda, Helsingborg, Sweden) was inserted into a cubital
vein. Thirty minutes after puncture of the vein, baseline
recordings and blood samplings were performed. When
changes in the electrode position occurred, the experiment was
discarded.
The following protocols were performed (Fig. 1). In proto-
col 1, muscle sympathetic nervous activity (MSA) was mea-
sured in 10 patients treated with nifedipine 10 mg. In protocol
2, MSA was measured in 6 patients treated with nifedipine,
5 mg. In protocol 3, skin sympathetic activity (SSA) was
measured in 5 patients treated with nifedipine, 10 mg. In
protocol 4, MSA was measured in 10 patients treated with
nifedipine GITS, 60 mg (slow-release form), or placebo. The
latter subjects were reexamined on 2 subsequent days, as it is
difficult to record MSA for the time period required to achieve
maximal nifedipine plasma levels with the GITS formulation.
Hence, on day 2, 5 subjects received nifedipine GITS, 60 mg,
180 min before the experiments were started. In protocol 5, 5
subjects of protocol 4 underwent an infusion study with
esmolol (300, 1,000 and 2,000 mg/kg body weight) and atropine
(1, 3 and 10 mg/kg); the drugs were injected before and after
both nifedipine, 10 mg, and nifedipine GITS, 60 mg. These
experiments were performed to unmask the sympathetic (es-
molol [20]) or parasympathetic (atropine [21]) portion of the
relative changes in HR (Fig. 1).
All subjects underwent a cold pressor test, with and without
drug administration, in which they immersed one hand (up to
the wrist) in ice water for 2 min. After the test, the subjects
received nifedipine, 5 or 10 mg, nifedipine GITS, 60 mg, or
placebo). When estimated peak drug plasma levels were
achieved (i.e., 30 min after ingestion of nifedipine, 5 or 10 mg,
or 150 min after ingestion of nifedipine GITS or placebo, the
test was repeated. In the experiments on day 2, the subjects
ingested the drug (nifedipine GITS, 60 mg) 180 min before the
test. The test was then repeated 360 min after drug ingestion.
If muscle contractions occurred during the maneuvers, causing
electromyographic artifacts in the neurogram, the results of
the test were discarded.
Blood samples for catecholamine determinations were ob-
tained at baseline and 30 min (150 min for nifedipine GITS)
after drug administration. Blood samples for plasma levels of
nifedipine were obtained at baseline as well as after 20, 30 and
60 min (nifedipine, 5 and 10 mg) and every 30 min up to
360 min (nifedipine GITS) after drug ingestion.
Microneurography. Multifiber recordings of MSA were
obtained from peroneal nerve posterior to the fibular head
with tungsten microelectrodes (200-mm shaft diameter: 1 to
5 mm; uninsulated tip). A reference electrode was inserted
subcutaneously 1 to 2 cm from the recording electrode. Signal
processing was performed as described (22). The signal was
displayed on an oscilloscope and registered on a thermo-
Abbreviations and Acronyms
BP 5 blood pressure
ECG 5 electrocardiogram, electrocardiographic
HR 5 heart rate
GITS 5 gastrointestinal therapeutic system (slow-release formulation
of nifedipine)
MSA 5 muscle sympathetic nerve activity
SNS 5 sympathetic nervous system
SSA 5 skin sympathetic nerve activity
Figure 1. Schematic explaining
the protocols performed. Atrop 5
atropine; CP 5 cold pressor.
1608 WENZEL ET AL. JACC Vol. 29, No. 7
NIFEDIPINE ACTIVATES SYMPATHETIC NERVE ACTIVITY June 1997:1607–14
coupled printer at a paper speed of 5 mm/s (Graphtec Inc,
Yokokawa, Japan). In addition, the nonintegrated signal was
recorded on the printer to better identify artifacts. The criteria
for acceptance of MSA were selected according to published
data (23). Neurograms with SSA or mixed SSA and MSA were
not accepted. For recordings of SSA, the microelectrode was
placed in an area of skin-sensible afference as described (24).
Accordingly, if there was any evidence of dislocation of the
electrode position, the experiment was discarded from the
study.
ECG, blood pressure, respiration. An ECG was recorded
simultaneously on the printer throughout the study. Blood
pressure was assessed noninvasively with oscillometric occlu-
sion (Dinamap).
Drugs. Nifedipine, 5 mg and 10 mg, and slow-release
nifedipine (GITS), 60 mg, were given as tablets (Adalat and
Adalat CR, Bayer Leverkusen, Germany). For the placebo
experiments, identical tablets without active drug were used.
Atropine (Sintetica, Mendrisio, Switzerland) and esmolol
(Gensia-Opopharma, Zurich, Switzerland) were given as intra-
venously injected solutions after appropriate dilution with
saline solution (0.9%, Inselspital, Bern, Switzerland).
Plasma levels of drug and hormones. Nifedipine plasma
levels were determined in human plasma by automated
electron-capture capillary gas chromatography according to
the gas chromatography method (25), with modified and
validated gas chromatography conditions (ANAWA Laborato-
ries, Zurich).
Plasma catecholamines were determined by high perfor-
mance liquid chromatography; plasma endothelin was deter-
mined by radioimmunoassay (hypertension laboratory, Univer-
sity Hospital, Bern).
Analysis and statistics. MSA was assessed by counting the
bursts/min as well as by calculating an arbitrary burst index
depending on the amplitude of the bursts. Data are given as
mean value 6 SEM. We performed an analysis of variance test
for treatment (placebo and nifedipine, 5 and 10 mg) and a
Bonferroni post-hoc t test. For nifedipine GITS, 60 mg, a
paired t test was performed to assess the statistical difference
versus placebo. For the dose-response curves of atropine and
esmolol, the area under the curve was calculated and a paired
t test performed. For the studies with SSA and the cold pressor
test experiments, a paired t test was performed. A p value
#0.05 was taken for statistical significance.
Results
Baseline Conditions
MSA and SSA. Under baseline conditions, MSA was sim-
ilar in all treatment groups. In the placebo group, MSA
(bursts/min and burst index) tended to increase slightly but not
significantly during the experiment (Fig. 2, left panel). After
administration of nifedipine, 5 mg, MSA remained unchanged
(p 5 NS), but it increased markedly after administration of
nifedipine, 10 mg, or nifedipine GITS, 60 mg (p , 0.05 vs.
placebo, Fig. 2, left panel). In contrast to MSA, SSA did not
change from baseline conditions after nifedipine, 10 mg (12 6
3 before vs. 14 6 3 bursts/min) after nifedipine (p 5 NS).
Thirty minutes after oral administration of nifedipine, 5 or
10 mg, plasma nifedipine levels were 9 6 5 and 23 6 7 ng/ml,
respectively (p , 0.05 and 0.001). Peak plasma levels were
achieved within 60 min after nifedipine, 5 mg (11.6 6 6 ng/ml,
p , 0.05), and within 40 min after nifedipine, 10 mg (29 6
8 ng/ml, p , 0.001). After administration of nifedipine GITS,
60 mg, nifedipine plasma levels were 3 6 1 ng/ml within 150
minutes after drug administration; peak plasma levels were
reached within 330 min and averaged 12 6 3 ng/ml.
HR and BP. At baseline, HR (Table 1) and BP (data not
shown) were comparable in all treatment groups. After drug
Figure 2. MSA expressed as bursts/min (left panel) and HR (right
panel) before and after oral nifedipine (5 mg; 10 mg; GITS, 60 mg) or
placebo. bpm 5 beats per minute.
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administration, HR increased only in the group treated with
nifedipine; 10 mg (p , 0.01), but not in the remaining groups
including the group receiving nifedipine GITS, 60 mg (p 5 NS;
Table 1; Fig. 2, right panel).
At baseline, parasympathomimetic doses of atropine (1 and
3 mg/kg) slightly decreased HR, whereas the parasympatholytic
dose (10 mg/kg) significantly increased HR (p , 0.01; Fig. 3,
left panel). The response to atropine after nifedipine, 10 mg, or
nifedipine GITS, 60 mg, was similar (p 5 NS; Fig. 3, left
panel).
At baseline, cardiac beta1-receptor blockade with esmolol
induced a significant decrease in HR (p , 0.01; Fig. 3, right
panel). After nifedipine, 10 mg, HR tended to decrease more
than under baseline conditions (p 5 NS vs. control; Fig. 3, right
panel), whereas after nifedipine GITS, 60 mg, the decrease was
similar to baseline conditions (p 5 NS vs. control; Fig. 3, right
panel).
Systolic BP of these normotensive subjects did not change
after drug administration in either group (p 5 NS, data not
shown); diastolic blood pressure decreased slightly after nifed-
ipine, 10 mg (25 6 2 mm Hg, p , 0.01), whereas it slightly
increased 150 min after nifedipine GITS, 60 mg (15 6
3 mm Hg, p , 0.05).
Plasma catecholamines. Plasma norepinephrine markedly
increased 30 min after nifedipine, 10 mg (from 160 6 21 to
238 6 26 pg/ml [n 5 4], p , 0.05), whereas the increase in
plasma epinephrine was not statistically significant (from 19 6
7 to 37 6 11 pg/ml [n 5 4], p 5 NS vs. baseline). After
nifedipine GITS, 60 mg, plasma norepinephrine increased
150 min after drug intake (from 147 6 33 to 214 6 45 pg/ml
[n 5 10], p , 0.05), further increased 300 min after nifedipine
GITS, 60 mg, on day 2 (264 6 112 pg/ml [n 5 5], p 5 NS vs.
baseline) and decreased again after 360 min (172 6 21 pg/ml
[n 5 5], p 5 NS vs. baseline). Plasma epinephrine values
Table 1. HR (beats/min) in Healthy Human Subjects Receiving Nifedipine or Placebo Under Baseline




30 min 150 min 180 min 360 min
Baseline
Nifedipine, 5 mg (n 5 6) 72 6 5 76 6 6 — — —
Nifedipine, 10 mg (n 5 10) 64 6 2 71 6 3* — — —
Nifedipine GITS, 60 mg (n 5 10) 62 6 2 57 6 2 63 6 2 65 6 1 65 6 3
Placebo (n 5 5) 62 6 5 55 6 3 57 6 3 — —
HR D During cold pressor test
Nifedipine, 5 mg (n 5 6) 15 6 2 16 6 2† — — —
Nifedipine, 10 mg (n 5 10) 14 6 2 16 6 2† — — —
Nifedipine GITS, 60 mg (n 5 10) 15 6 2 — 17 6 2† 18 6 2 18 6 3
Placebo (n 5 5) 17 6 2 — 111 6 5 — —
*p , 0.01 versus placebo. †p , 0.05 versus baseline. Data are presented as mean value 6 SEM. GITS 5
gastrointestinal therapeutic system (slow-release formulation of nifedipine); HR 5 heart rate; D 5 change; — 5 not
done.
Figure 3. Changes in HR after
different doses of atropine (At-
rop) (left panel) or esmolol (right
panel) before and after short-
acting (10 mg orally) or slow-
release nifedipine (GITS, 60 mg).
Note that atropine at low doses
slightly decreased HR, whereas it
markedly increased HR at the
high dose (p , 0.001 vs. baseline).
Treatment with nifedipine did not
alter the response to atropine
(p 5 NS vs. control [left panel]).
Esmolol dose-dependently de-
creased HR (p , 0.001 vs. base-
line [right panel]), whether or not
the subjects had been pretreated
with slow-release nifedipine (p 5
NS vs. control). After pretreat-
ment with short-acting nifedipine,
decreases in HR tended to be
higher, indicating a higher sympa-
thetic tone (p 5 NS vs. control).
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tended to increase after both nifedipine, 10 mg, and nifedipine
GITS, 60 mg (nifedipine, 10 mg, from 19 6 7 to 37 6 11 pg/ml
[n 5 4], p 5 NS; nifedipine GITS, 60 mg, from 51 6 10 to 64 6
25 pg/ml [n 5 10], p 5 NS vs. baseline; peak value 330 min
after drug intake 85 6 42 pg/ml [n 5 5], p 5 NS vs. baseline).
Plasma endothelin. At baseline, plasma endothelin was
2.1 6 0.1 pg/ml. After nifedipine, 10 mg, it tended to increase
(2.2 6 0.1 pg/ml, p 5 NS), whereas it increased markedly 6 h
after nifedipine GITS, 60 mg (2.9 6 0.4 pg/ml, p , 0.05 [n 5
5]).
Cold Pressor Test
MSA and SSA. Under control conditions, the cold pressor
test led to the strongest increase in MSA in all treatment
groups (p , 0.01 to p , 0.05; Fig. 4). Although MSA increased
(p , 0.05) after both nifedipine, 10 mg, and nifedipine GITS,
60 mg, the cold pressor test increased MSA further and in an
additive fashion. However, the difference between the increase
of MSA with the cold pressor test and MSA under baseline
conditions was significant only in the placebo group (p 5 0.05;
Fig. 4) and in the group treated with nifedipine, 10 mg (p ,
0.05 vs. control; Fig. 4).
Under control conditions, SSA increased significantly with
the cold pressor test (110 6 2 bursts/min, p , 0.01). However,
after nifedipine, 10 mg, the increase in SSA during the cold
pressor test was less pronounced (16 6 2 bursts/min, p , 0.05
vs. control).
HR and BP. HR tended to increase with the cold pressor
test under control conditions (p 5 NS; Table 1), whereas both
systolic and diastolic BP markedly increased with the test
(122 6 2/120 6 1 mm Hg [systolic/diastolic], p , 0.01 to p ,
0.05). HR during the cold pressor test was significantly higher
after nifedipine, 10 mg (p , 0.001 vs. control), but not after
nifedipine GITS, 60 mg (p 5 NS; Table 1). Both systolic and
diastolic BP were similar during the cold pressor test before
and after nifedipine, 10 mg, and nifedipine GITS, 60 mg (p 5
NS; data not shown).
Discussion
This study is the first to demonstrate with direct measure-
ment of sympathetic nerve activity in the peroneal nerve in
humans that nifedipine independent of the drug release for-
mulation, is a strong stimulator of peripheral sympathetic
nerve traffic. However, with the short-acting compound, both
cardiac sympathetic activity (i.e., HR) and MSA increased, but
with the slow-release preparation, HR remained unchanged
although MSA increased to a similar degree. There was no
increase in cardiac parasympathetic tone after nifedipine
GITS. Nifedipine did not affect SSA.
Role of SNS in cardiovascular disease. The SNS is an
important regulator of the circulation whose activity is deter-
mined by psychologic, neuronal and humoral factors (26). The
effects of cardiovascular drugs on the SNS have been studied
little and are most commonly assessed by measuring plasma
catecholamines. However, plasma catecholamine determina-
tions provide only an indirect measure of sympathetic nerve
activity because only the overflow of the adrenergic neuro-
transmitter from the synaptic cleft is measured. Furthermore,
plasma catecholamine levels reflect the activity not only of
adrenergic neurons, but also of the adrenal medulla. Finally,
most methods of measuring plasma catecholamines are prone
to considerable variation. In contrast, microneurography di-
Figure 4. Changes in MSA induced by a cold
pressor test before and after oral nifedipine
(5 mg; 10 mg; GITS, 60 mg) or placebo. *p ,
0.05, **p , 0.01 versus control.
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rectly records sympathetic nerve traffic (23,27). Because the
signals can be obtained on-line, the method allows recordings
of small and short-lasting changes and their time course during
stimulatory maneuvers. The latter property of microneurogra-
phy allows characterization of changes in sympathetic nerve
activity during administration of a cardiovascular drug and
analysis of the importance of pharmacokinetic properties of a
given preparation under these conditions.
Effects of nifedipine on SNS. Our study confirms previous
reports of the effects of nifedipine, 10 mg, in particular the
increase in HR occurring after application of a short-acting
dihydropyridine in humans (28–31). Furthermore, our micro-
neurographic data show that under these conditions a parallel
increase in MSA traffic as well as an increase in norepineph-
rine plasma levels also occurs. The degree of activation of
MSA was impressive and comparable to that obtained with a
cold pressor test, one of the strongest activators of MSA (32).
Even more surprising than the degree of activation of MSA
was the fact that in subjects receiving nifedipine the system
could be further stimulated during the cold pressor test to a
degree similar to that without the drug and—especially with
nifedipine, 10 mg—in addition to an already increased baseline
activity. This finding indicates that with short-acting dihydro-
pyridines, the peripheral and cardiac portions of the SNS are
highly activated and remain as responsive to these stimulatory
maneuvers as they are in untreated subjects.
SSA was not influenced by nifedipine, 10 mg, indicating that
this part of the SNS is regulated by different mechanisms. This
observation underscores the concepts that sympathetic outflow
is not uniformly regulated but specifically targeted to different
organs and tissues and that nifedipine acts on the part of the
SNS regulated by the baroreflex.
Effects of slow-release nifedipine (GITS) on cardiac SNS.
Gastrointestinal therapeutic systems (GITS) have been devel-
oped to change the pharmacokinetic properties of short-acting
molecules. The pharmacokinetics of nifedipine GITS, 60 mg, is
very different from that of the original formulation (33,34).
Indeed, peak plasma levels were reached within 40 to 60 min
after oral administration of nifedipine, 5 or 10 mg, whereas
they occurred at 330 min after administration of nifedipine
GITS, 60 mg. It has been suspected that activation of the SNS
might depend on the pharmacokinetics of the drugs, that is, on
the speed of unloading of the carotid baroreceptors. On the
bases of these short-term experiments, it appears that—in
contrast to short-acting nifedipine—nifedipine GITS, 60 mg,
results in no change in cardiac sympathetic outflow. Indeed,
HR did not change significantly with nifedipine GITS, 60 mg,
whereas a marked increase was noted with nifedipine, 10 mg.
Furthermore, increases in HR over control values in response
to parasympatholytic dosages of atropine were similar after
both short-acting and slow-release nifedipine; therefore, the
missing increase in HR after slow-release nifedipine is not due
to increased parasympathetic tone. In contrast, the decrease in
HR after cardiac sympatholysis with esmolol was similar with
and without nifedipine GITS, whereas it was slightly higher
after short-acting nifedipine; this finding demonstrates, that
after slow-release nifedipine as opposed to short-acting nifed-
ipine, cardiac sympathetic activation does not occur despite a
marked increase in peripheral sympathetic tone.
Effects of slow-release nifedipine (GITS) on peripheral
SNS. In contrast to cardiac sympathetic outflow, MSA showed
a completely different pattern. Under both conditions, that is,
with administration of the short-acting and the long-acting
forms of nifedipine—MSA increased quite dramatically and to
a similar level, although peak nifedipine plasma levels were
actually lower with nifedipine GITS, 60 mg, than with nifedi-
pine, 10 mg. The only difference between the two preparations
was the more subtle onset of MSA with the slow-release form.
Indirect measurements of sympathetic activity measuring fore-
arm blood flow and forearm norepinephrine spillover (28)
have suggested an increase of sympathetic activity despite a
lack of heart rate increase during both short- and long-term
treatment with the calcium channel antagonist felodipine in
hypertensive patients. Hence, our study directly demonstrates
that the SNS is not uniformly activated and that cardiac
sympathetic activity and MSA are differentially regulated. It
appears that with a rapid onset of vasodilation (induced in this
instance by calcium channel antagonists), the cardiovascular
system attempts to compensate for these changes by a gener-
alized increase in sympathetic nerve activity leading to in-
creased HR and peripheral vascular resistance. This may
explain why, despite rather high drug levels of nifedipine, BP
changed only very slightly in these normotensive subjects and
no hypotension occurred. With a more subtle onset of vasodi-
lation with a slow-release preparation of nifedipine, it appears
to be sufficient to selectively increase MSA while leaving HR
unchanged. Possibly, baroreflex sensitivity controlling HR
adapts rapidly with the slow-release formulation, whereas
peripheral sympathetic activity is still activated (29).
Plasma norepinephrine and plasma endothelin levels in-
creased after nifedipine GITS, 60 mg. The fact that plasma
endothelin levels increased only after slow-release nifedipine
indicates that endothelin is newly synthesized, which takes
several hours (35). Catecholamines such as epinephrine, which
stimulate the synthesis of endothelin, may be potential medi-
ators (36). The increases in MSA, plasma norepinephrine and
plasma endothelin explain why, despite a missing increase in
HR, BP did not decrease after nifedipine GITS.
Potential therapeutic implications. These findings may
have important therapeutic implications. Indeed, the fact that
plasma norepinephrine levels are a very strong predictor of
mortality in patients with heart failure (5) suggests that
activation of the SNS is detrimental at least in these patients,
but possibly also in other patient groups, such as those with
hypertension (12). Indeed, it has been well documented (37)
that short-acting calcium channel antagonists should not be
used in unstable clinical situations such as hypertensive crisis
or myocardial ischemia. Whether slow-release formulations of
nifedipine are safe in hypertensive patients with or without
coronary artery disease is under investigation.
Although the data of the present study cannot necessarily
be extrapolated to patients with heart failure or hypertension,
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as both baroreflex control and baseline sympathetic activity are
altered under these conditions, assessment of the effects of
cardiovascular drugs on the SNS may be an important step in
the evaluation of these patients. Indeed, angiotensin-
converting enzyme inhibitors such as captopril do slightly lower
MSA under the same experimental conditions applied in the
present study (38). Similarly, it is likely that all drugs activating
the SNS are detrimental in patients with an acute coronary
syndrome (37). However, the differential regulation of periph-
eral and cardiac sympathetic outflow, particularly with slow-
release forms of dihydropyridines but potentially also with
other drugs, suggests that the effects of short-acting drugs and
slow-release forms may differ considerably in these particular
clinical syndromes.
Potential mechanisms. Examination of the mechanism of
activation of the SNS by dihydropyridine calcium channel
antagonists is beyond the scope of this study. Most likely,
however, the vasodilation leads to an activation of baroreflex
activity and, in turn, to a stimulation of sympathetic outflow. A
direct stimulation of the SNS through central mechanisms by
dihydropyridines is unlikely. Indeed, there are no experimental
data supporting such an interpretation, although these drugs
are able to reach tissues of the central nervous system (39).
Conclusions. The lack of an increase in HR demonstrates
a differential regulation of cardiac and peripheral sympathetic
activity. Therefore, changes in HR do not necessarily reflect
changes in the peripheral SNS and cannot be used as a
surrogate for the measurement of the activity of this important
regulatory mechanism when vasoactive drugs are tested.
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